279 related articles for article (PubMed ID: 29046735)
1. Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma.
Luebeck EG; Curtius K; Hazelton WD; Maden S; Yu M; Thota PN; Patil DT; Chak A; Willis JE; Grady WM
Clin Epigenetics; 2017; 9():113. PubMed ID: 29046735
[TBL] [Abstract][Full Text] [Related]
2. Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use.
Kaz AM; Wong CJ; Varadan V; Willis JE; Chak A; Grady WM
Clin Epigenetics; 2016; 8():111. PubMed ID: 27795744
[TBL] [Abstract][Full Text] [Related]
3. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.
Eads CA; Lord RV; Kurumboor SK; Wickramasinghe K; Skinner ML; Long TI; Peters JH; DeMeester TR; Danenberg KD; Danenberg PV; Laird PW; Skinner KA
Cancer Res; 2000 Sep; 60(18):5021-6. PubMed ID: 11016622
[TBL] [Abstract][Full Text] [Related]
4. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.
Kaz AM; Wong CJ; Luo Y; Virgin JB; Washington MK; Willis JE; Leidner RS; Chak A; Grady WM
Epigenetics; 2011 Dec; 6(12):1403-12. PubMed ID: 22139570
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic patterns in the progression of esophageal adenocarcinoma.
Eads CA; Lord RV; Wickramasinghe K; Long TI; Kurumboor SK; Bernstein L; Peters JH; DeMeester SR; DeMeester TR; Skinner KA; Laird PW
Cancer Res; 2001 Apr; 61(8):3410-8. PubMed ID: 11309301
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
8. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A
Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291
[TBL] [Abstract][Full Text] [Related]
9. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
Smith E; De Young NJ; Pavey SJ; Hayward NK; Nancarrow DJ; Whiteman DC; Smithers BM; Ruszkiewicz AR; Clouston AD; Gotley DC; Devitt PG; Jamieson GG; Drew PA
Mol Cancer; 2008 Oct; 7():75. PubMed ID: 18831746
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
11. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma.
Wu W; Bhagat TD; Yang X; Song JH; Cheng Y; Agarwal R; Abraham JM; Ibrahim S; Bartenstein M; Hussain Z; Suzuki M; Yu Y; Chen W; Eng C; Greally J; Verma A; Meltzer SJ
Gastroenterology; 2013 May; 144(5):956-966.e4. PubMed ID: 23333711
[TBL] [Abstract][Full Text] [Related]
13. Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression.
Kuester D; Dar AA; Moskaluk CC; Krueger S; Meyer F; Hartig R; Stolte M; Malfertheiner P; Lippert H; Roessner A; El-Rifai W; Schneider-Stock R
Neoplasia; 2007 Mar; 9(3):236-45. PubMed ID: 17401463
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.
Hao Y; Triadafilopoulos G; Sahbaie P; Young HS; Omary MB; Lowe AW
Gastroenterology; 2006 Sep; 131(3):925-33. PubMed ID: 16952561
[TBL] [Abstract][Full Text] [Related]
15. Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
Kaz AM; Luo Y; Dzieciatkowski S; Chak A; Willis JE; Upton MP; Leidner RS; Grady WM
Genes Chromosomes Cancer; 2012 Apr; 51(4):384-93. PubMed ID: 22170739
[TBL] [Abstract][Full Text] [Related]
16. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.
Hamilton JP; Sato F; Jin Z; Greenwald BD; Ito T; Mori Y; Paun BC; Kan T; Cheng Y; Wang S; Yang J; Abraham JM; Meltzer SJ
Clin Cancer Res; 2006 Nov; 12(22):6637-42. PubMed ID: 17121882
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic biomarkers in esophageal cancer.
Kaz AM; Grady WM
Cancer Lett; 2014 Jan; 342(2):193-9. PubMed ID: 22406828
[TBL] [Abstract][Full Text] [Related]
19. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.
Peng DF; Razvi M; Chen H; Washington K; Roessner A; Schneider-Stock R; El-Rifai W
Gut; 2009 Jan; 58(1):5-15. PubMed ID: 18664505
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus.
Clément G; Guilleret I; He B; Yagui-Beltrán A; Lin YC; You L; Xu Z; Shi Y; Okamoto J; Benhattar J; Jablons D
Cancer Sci; 2008 Jan; 99(1):46-53. PubMed ID: 18005197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
